Welcome to ALTG

Feasibility is open for the ILLUMINATE Study (ALTG 16/009) which is a phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor (EGFR) mutation Tyrosine Kinase Inhibitors (TKIs).

ALTG Speaking Tour:
The purpose of this educational evening is to provide practical evidence-based strategies for use within the multidisciplinary team environment but also to identify potential gaps in research.

For Patients

Upcoming Events

Upcoming Events
  1. Open Management and Scientific Advisory Committee Meetings

    November 23